anti-CD3/41BB/IL-2 TIL-NP

N/A

Report date: 2026/04/17 10:36:10

Base Information

Drug Nameanti-CD3/41BB/IL-2 TIL-NP
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionAnti-CD3Anti-Tumor necrosis factor receptor superfamily member 9
TargetsT cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Texas Southwestern Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical Center
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A